Clinical and demographic factors modify the association between plasma phosphorylated tau-181 and cognition.

IF 4 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Pub Date : 2024-12-20 eCollection Date: 2024-10-01 DOI:10.1002/dad2.70047

Corey J Bolton, Marilyn Steinbach, Omair A Khan, Dandan Liu, Julia O'Malley, Logan Dumitrescu, Amalia Peterson, Angela L Jefferson, Timothy J Hohman, Henrik Zetterberg, Katherine A Gifford

{"title":"Clinical and demographic factors modify the association between plasma phosphorylated tau-181 and cognition.","authors":"Corey J Bolton, Marilyn Steinbach, Omair A Khan, Dandan Liu, Julia O'Malley, Logan Dumitrescu, Amalia Peterson, Angela L Jefferson, Timothy J Hohman, Henrik Zetterberg, Katherine A Gifford","doi":"10.1002/dad2.70047","DOIUrl":null,"url":null,"abstract":"Introduction: Plasma phosphorylated tau-181 (p-tau181) associations with global cognition and memory are clear, but the link between p-tau181 with other cognitive domains and subjective cognitive decline (SCD) across the clinical spectrum of Alzheimer's disease (AD) and how this association changes based on genetic and demographic factors is poorly understood.Methods: Participants were drawn from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and included 1185 adults >55 years of age with plasma p-tau181 and neuropsychological test data. Linear regression models related plasma p-tau181 to neuropsychological composite and SCD scores with follow-up models examining plasma p-tau181 interactions with cognitive diagnosis, apolipoprotein E (APOE) ε4 carrier status, age, and sex on cognitive outcomes.Results: Higher plasma p-tau181 level was associated with worse memory, executive functioning, and language abilities, and greater informant-reported SCD. Visuospatial abilities and self-report SCD were not associated with plasma p-tau181. Associations were generally stronger in mild cognitive impairment (MCI) or dementia, APOE ε4 carriers, women, and younger participants.Discussion: Higher levels of plasma p-tau181 are associated with worse neuropsychological test performance across multiple cognitive domains; however, these associations vary based on disease stage, genetic risk status, age, and sex.Highlights: Greater plasma p-tau181 was associated with lower cognition across most domains.Associations between p-tau181 and cognition were modified by age and sex.Level of p-tau181 was more strongly associated with cognition in people with mild cognitive impairment (MCI) and apolipoprotein E (APOE) ε4.","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"16 4","pages":"e70047"},"PeriodicalIF":4.0000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11659951/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70047","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Plasma phosphorylated tau-181 (p-tau181) associations with global cognition and memory are clear, but the link between p-tau181 with other cognitive domains and subjective cognitive decline (SCD) across the clinical spectrum of Alzheimer's disease (AD) and how this association changes based on genetic and demographic factors is poorly understood.

Methods: Participants were drawn from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and included 1185 adults >55 years of age with plasma p-tau181 and neuropsychological test data. Linear regression models related plasma p-tau181 to neuropsychological composite and SCD scores with follow-up models examining plasma p-tau181 interactions with cognitive diagnosis, apolipoprotein E (APOE) ε4 carrier status, age, and sex on cognitive outcomes.

Results: Higher plasma p-tau181 level was associated with worse memory, executive functioning, and language abilities, and greater informant-reported SCD. Visuospatial abilities and self-report SCD were not associated with plasma p-tau181. Associations were generally stronger in mild cognitive impairment (MCI) or dementia, APOE ε4 carriers, women, and younger participants.

Discussion: Higher levels of plasma p-tau181 are associated with worse neuropsychological test performance across multiple cognitive domains; however, these associations vary based on disease stage, genetic risk status, age, and sex.

Highlights: Greater plasma p-tau181 was associated with lower cognition across most domains.Associations between p-tau181 and cognition were modified by age and sex.Level of p-tau181 was more strongly associated with cognition in people with mild cognitive impairment (MCI) and apolipoprotein E (APOE) ε4.

查看原文本刊更多论文

临床和人口统计学因素改变了血浆磷酸化tau-181与认知之间的关系。

血浆磷酸化的tau-181 （p-tau181）与整体认知和记忆的关联是明确的，但p-tau181与其他认知域和阿尔茨海默病（AD）临床谱中的主观认知衰退（SCD）之间的联系以及这种关联如何基于遗传和人口统计学因素发生变化尚不清楚。方法：参与者来自阿尔茨海默病神经影像学倡议（ADNI），包括1185名年龄在0至55岁之间的成年人，他们的血浆p-tau181和神经心理测试数据。线性回归模型将血浆p-tau181与神经心理综合和SCD评分相关，随访模型检测血浆p-tau181与认知诊断、载脂蛋白E (APOE) ε4携带者状态、年龄和性别对认知结果的相互作用。结果：较高的血浆p-tau181水平与较差的记忆、执行功能和语言能力以及更大的线人报告的SCD相关。视空间能力和自我报告SCD与血浆p-tau181无关。在轻度认知障碍（MCI）或痴呆、APOE ε4携带者、女性和年轻参与者中，相关性通常更强。讨论：血浆p-tau181水平升高与多个认知领域的神经心理测试表现较差有关；然而，这些关联因疾病分期、遗传风险状况、年龄和性别而异。重点：血浆p-tau181升高与大多数领域的认知能力降低相关。p-tau181与认知之间的关联因年龄和性别而改变。p-tau181水平与轻度认知障碍（MCI）和载脂蛋白E (APOE) ε4的认知能力相关性更强。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring Medicine-Psychiatry and Mental Health

CiteScore

7.80

自引率

7.50%

发文量

101

审稿时长

8 weeks

期刊介绍： Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.